Pemigatinib User Reviews & Ratings
Brand names: Pemazyre
Pemigatinib has an average rating of 1.0 out of 10 from a total of 1 reviews on Drugs.com. 0% of reviewers reported a positive experience, while 100% reported a negative experience.
| Condition | Avg. Rating | Reviews | Compare |
|---|---|---|---|
| Cholangiocarcinoma | 1 reviews for Cholangiocarcinoma | 2 medications |
See also:
Reviews may be edited to correct grammar/spelling or remove inappropriate content. Reviews appearing to come from parties with a vested interest are not published. This information is not intended to endorse any medication and should not replace the expertise and judgment of healthcare professionals.
More about pemigatinib
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: multikinase inhibitors
- Breastfeeding
- En español
For Cholangiocarcinoma "My husband has completed 3 rounds of 13.5 mg Pemazyre. He has had a problem with ascites in his abdomen and has been receiving paracentesis 2x per week. Originally, he had been averaging 8-10 liters each time during chemotherapy. He completed 6 rounds that failed to help him. He started the Pemazyre, and the yield of the paracentesis dropped steadily to 4-6 liters. An encouraging sign!!! He has had a number of side effects: hair loss, taste loss, ache in his jaw, pain in his limb muscles. During the second week of his 3rd round, a bruise on his calf began to look like blood under the skin and continued to spread, causing great pain and eventual hospitalization. Apparently, this is a rare and serious side effect and may involve calcium blocking blood vessels and flow. At that same time, a nearly 100% loss of vision has occurred - blind!!! A corner of the retina has lifted, and we pray it goes back into place to return his eyesight. Doubtful my husband will continue a low dose."